Health Condition 1: - Health Condition 2: C921- Chronic myeloid leukemia, BCR/ABL-positive
Conditions
Interventions
None listed
Sponsors
DR BRA IRCH AIIMS
Eligibility
Inclusion criteria
Inclusion criteria: a). Age >= 18 years b). CML-CP on imatinib mesylate c). Optimal response to imatinib d). Minimum duration of imatinib mesylate treatment of 3 years e) At least complete molecular remission MR4 f). Deep molecular remission duration should be at least one year g) Baseline data and documentation of treatment should be available for outside treated patients
Exclusion criteria
Exclusion criteria: a) Patients who had CML-accelerated phase/ blast crisis at diagnosis b) High Sokal score c). Not willing for the study d) Pregnancy e) Female patient not willing to use contraception f) Patients not willing for regular follow up
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| TO DETERMINE DURATION OF COMPLETE MOLECULAR RESPONSE IN SUBJECTS AFTER STOPPING IMATINIB MESYLATE THERAPYTimepoint: AT END OF 2 YEARS FROM ENROLMENT | — |
Secondary
| Measure | Time frame |
|---|---|
| IDENTIFICATION OF CLINICAL AND LABORATORY PREDICTORS OF PERSISTENCE COMPLETE MOLECULAR RESPONSE AFTER STOPPING IMATINIB MESYLATETimepoint: AT END OF 2 YEARS FROM ENROLMENT;TO EVALUATE QUALITY OF LIFE IN PATIENTS AFTER STOPPING IMATINIB MESYLATETimepoint: AT ENROLMENT IN THIS STUDY | — |
Countries
India
Contacts
Public ContactDr Lalit Kumar
AIIMS
Outcome results
None listed